Lactobacillus salivarius

L. salivarius produces high quantities of lactic acid, lowering local pH and creating an environment less favorable for many pathogenic bacteria. It also produces salivaricins, antimicrobial peptides that can inhibit competing organisms, including those involved in dental decay and gum disease. In the gastrointestinal tract, L. salivarius adheres to intestinal epithelial cells and competes with potentially harmful bacteria for nutrients and binding sites. It interacts with the gut-associated immune system, modulating cytokine production and potentially supporting more balanced immune responses. Certain strains have been studied for their ability to strengthen intestinal barrier integrity and reduce inflammation. The oral cavity is a notable habitat for L. salivarius, and certain strains have been developed for use in oral lozenges and chewable tablets targeting halitosis, gum health, and reduction of cavity-causing Streptococcus mutans. Strain-specific effects are important: the documented uses of L. salivarius UCC118 (gut applications) differ from those of L. salivarius K12 (oral applications, though K12 is actually a Streptococcus species).

There is no RDA for probiotics. Clinical studies of L. salivarius typically use 1 to 10 billion CFU per day. Oral health applications often use lozenges containing 100 million to 1 billion CFU per lozenge, used after meals. Commercial supplements commonly provide 1 to 10 billion CFU per capsule.

L. salivarius can be taken with or without food. For gut applications, taking with a small meal may improve survival through the stomach. For oral applications, use lozenges after brushing and before bed when possible, allowing them to dissolve slowly for maximum mucosal contact. Avoid eating or drinking for 30 minutes after oral use. Separate from antibiotics by at least 2 hours.

L. salivarius is generally well tolerated. Mild gas, bloating, or digestive changes can occur initially. Serious adverse events are rare in healthy people. As with other live probiotics, immunocompromised individuals face a small but documented risk of bacteremia. There is no established Tolerable Upper Intake Level.

Antibiotics, including topical oral antimicrobials, can kill probiotic organisms; separate doses by at least 2 hours. Immunosuppressive medications may increase the small risk of bacterial translocation. No well-documented interactions with most supplements or medications. Use after, not concurrent with, antiseptic mouthwashes for oral applications.